Biosimilar inspections still lagging as the FDA looks to clear its backlog

While biosimilars are seeing greater recognition from the federal government, most notably HHS’ Office of the Inspector General highlighting their cost-saving abilities, the inspection of manufacturing sites producing them is still lagging.